AIP Corporate presentation

Page 1

Page 2

Disclaimer © 2026 Arteris, Inc.2 This presentation and the accompanying oral presentation have been prepared by Arteris, Inc. ("Arteris“ or “the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Arteris or any officer, director, employee, agent or advisor of Arteris. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Information provided in this presentation and the accompanying oral presentation speak only as of the date hereof. This presentation and the accompanying oral presentation include express and implied "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "project," "will," "would," "should," "could," "can," "predict," "potential," "target," "explore," "continue," or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These statements may relate to our market size and growth strategy including our estimated organic license revenue growth rate, estimate royalty revenue growth rate and number of M&A transactions targeted, our estimated and projected costs, margins, revenue, expenditures and growth rates (including our 1 st quarter and 2026 full year guidance), our future results of operations or financial condition, our plans and objectives for future operations, growth, initiatives, or strategies. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. These assumptions , uncertainties and risks include, among others, risks related to: market conditions and global economic factors, our ability to access debt and equity financing, our efforts to establish and maintain proper and effective internal controls, and other factors relating to our business, operations and financial performance. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results or outcomes to differ materially from those contained in any forward-looking statements we may make. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we, nor any other person, assumes responsibility for the accuracy and completeness of these statements. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. Except to the extent required by federal securities laws, we undertake no obligation to update any information or any forward-looking statements as a result of new information, subsequent events, or any other circumstances after the date hereof, or to reflect the occurrence of unanticipated events. This presentation and the accompanying oral presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk. In addition to the financials presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation includes the following non-GAAP metrics: non-GAAP operating expenses, non-GAAP operating income (loss) and free cash flow. Non-GAAP metrics have limitations as analytical tools and you should not consider them in isolation or as a substitute for or superior to the most directly comparable financial measures prepared in accordance with U.S. GAAP. There are a number of limitations related to the use of non-GAAP metrics versus their nearest GAAP equivalents. Other companies, including companies in our industry, may calculate non-GAAP metrics differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP metrics as tools for comparison. We urge you to review the reconciliation Arteris' non-GAAP metrics to the most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. See the Appendix for reconciliation between each non-GAAP metric and the most comparable GAAP measure. Arteris is unable to provide a reconciliation of certain non-GAAP guidance metrics in this presentation because the corresponding GAAP measures are not accessible on a forward-looking basis. Due to the potential variability and limited visibility of the excluded items, providing such reconciliation would necessitate unreasonable effort. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Page 3

Semiconductors Process Data, Store Data and Move Data Optimizing data transport critical to function, performance & power efficiency © 2026 Arteris, Inc.3 System IP (NoCs) data movement Processors data processing/compute Logic peripheral compute Memory data storage https://vimeo.com/1163376621/dc30108e1f

Page 4

Arteris Improves Data Movement in SoCs & Between Chiplets – From smart electronics to the most complex autonomous systems © 2026 Arteris, Inc.4 Expanding AI workloads drive chip complexity and the value of efficiently moving data across chiplets & SoCs  Multi-billion $ market  With 10-15% CAGR Expanding Arteris’ business opportunity for commercial system IP Arteris Product Lines SoC Integration Software  SoC system-level connectivity  Hardware-software integration  IP block packaging Network-on-Chip IP  Cache coherent NoC IP  Non-coherent NoC IP  Data movement options Hardware Security Assurance Software  HW Security Simulation  HW Security Emulation  HW Security Static Analysis

Page 5

Cycuity Radix-M Cycuity Radix-ST Cycuity Radix-S Magillem Connectivity Magillem Registers Magillem PackagingFlexGen FlexNoC FlexWay Trusted, Comprehensive, and Silicon Proven Products from Arteris © 2026 Arteris, Inc.5 Non-Coherent Network-on-Chip IP Ncore Cache Coherent Network-on-Chip IP SoC Integration Automation Software CodaCache Last-Level Cache IP Hardware Security Assurance Software + Size Options + Safety Options + Multi-Die Options + Size Options + Safety Options + Reliability Options IP, Chiplet, and SoC Assembly HW/SW Interface IP Block Packaging to IP-XACT HW Security Simulation HW Security Emulation HW Security Static Analysis

Page 6

Arteris Staying Ahead of Electronic System Innovation © 2026 Arteris, Inc.6 Adoption of New Semi. Technologies Smart Systems Connected Everywhere Regionalization of Semiconductor Industry More Processors & IP Blocks – data movement key competency – Government strategies, investments & subsidies Connections to the internet and each other Artificial Intelligence – electronic systems making decisions – Chiplets – multi-die SoCs go beyond Moore’s Law – MXM Network Ring Network Binary Time Network Supporting Silicon Based Business Creation Dramatic expansion of AI workloads - Arteris provides sophisticated solutions

Page 7

Arteris – The Leading System IP Company and NoC Pioneer Global customer base producing billions of SoCs © 2026 Arteris, Inc.7 System IP Leader  Pioneers of Network-on-Chip (NoC) IP  October 2021 IPO (Nasdaq: AIP)  Global Team of 300+ employees  115 patents issued, 146 applications1  ISO 9001:2015 and ISO 26262 Certified Proven Customer Successes  4B+ chips and chiplets shipped in electronic systems  925+ SoC design starts1  Used by 9 out of the top 10 semiconductor companies  90%+ customer retention rate2  Ecosystem: Any processor, any IP, any EDA, and any Foundry Tokyo Global R&D and Customer Support Campbell Seoul Taipei Bangalore Paris Tel-AvivAustin Nanjing Montigny Nice Kraków Tokyo Shanghai 1 As of December 31,2025 2 Over a three year period ending December 31,2025 Connected with the Ecosystem Diversified Customer Base Subset of Publicly Disclosed Customers

Page 8

Continuous Delivery of System IP Technology FlexGen smart NoC IP momentum since Q1`25 introduction © 2026 Arteris, Inc.8  Challenge: SoC design complexity has surpassed manual human capabilities, requiring smart NoC automation. Modern SoCs have 5 to 20+ unique NoC instances and each instance can require 5-10 iterations.  Solution: Automated NoC IP generation based on advanced algorithms, Incremental features and manual editing capability.  Benefits: to 10x better NoC IP productivity, to 30% shorter wire length, to 5% lower overall latency, lower power & competitive area vs manual NoCs.  Accelerating Momentum: – 31 licensed projects in 2025 – Multi-unit FlexGen orders from AMD and Altera

Page 9

 Challenge: With the rise of AI, computational power requirements are exceeding what is possible through traditional monolithic die designs.  Solution: Arteris Multi-Die Solution delivers foundational technology for rapid chiplet-based innovation across all markets.  Ecosystem: Collaboration for Multi-Die Physical Integration and Interoperability Arteris Expanding Multi-Die Solution to Meet Demand for Chiplets © 2026 Arteris, Inc.9

Page 10

Number of Customers (Dec 2025) Arteris Customers  275+ AI SoC design wins Data Center Training & Inference 30+ Edge Inference 60+ More Than 50% of Arteris Business is for AI Applications in 2025 © 2026 Arteris, Inc.10 Automotive OEM #1 Hyperscaler #5 Major Automotive OEM #1 Automotive OEM #2 Automotive OEM #3 Automotive OEM #4 Automotive OEM #5 Automotive OEM #6 BMW Toshiba Automotive OEM #7 Major Robotaxi #1Automotive OEM #8 Data movement is a key competency of AI SoCs  Arteris offers superior bandwidth & features Major US Hyperscaler #1 Hyperscaler #4Major US Hyperscaler #2 Major US Hyperscaler #3

Page 11

Key Arteris Customer and Ecosystem Highlights from Last Quarter © 2026 Arteris, Inc.11 NXP expanded its use of Arteris products including Ncore, FlexNoC, CodaCache, and Magillem software across its AI- enabled solutions for intelligent vehicles, advanced industrial systems, and consumer electronics at the edge. Black Sesame licensed Ncore and FlexNoC IP for its next generation of advanced automotive semiconductors Blaize deployed FlexNoC IP for its Blaize AI platform, delivering a programmable, energy-efficient solution spanning edge and cloud- based AI Arteris became a founding member of the CHASSIS program, an initiative led by Bosch and including OEMs such as BMW, Renault, and Stellantis, with the goal of creating an open Automotive chiplet platform Arteris joined Cadence’s recently announced strategic collaboration with Arm, Samsung Foundry and other IP partners to deliver pre- validated chiplet solutions for Physical AI

Page 12

15+ Year Relationship Between Mobileye and Arteris Supporting Mobileye leadership in automated driving and physical AI © 2026 Arteris, Inc12  MBLY SoC Generations 1. EyeQ7H - 2026 2. EyeQ6H 3. EyeQ6L 4. EyeQ5H 5. EyeQ5M 6. EyeQ4H 7. EyeQ4M 8. EyeQ3 - 2011

Page 13

Strategies for Arteris’ Multi-year Growth © 2026 Arteris, Inc.13 Organic product portfolio expansion  Jun. 2025 – Chiplet solution expansion  Feb. 2025 – FlexGen smart NoC IP production  Sep. 2024 – Magillem Registers production  Jun. 2023 – FlexNoC 5 production Focus on high growth segments & customers  Chiplets – AMD corporate contract  AI/ML – >50% of license $ in 2025 enable AI chiplet and SoC development  RISC-V – Alibaba in 3Q25  Automotive – 1 new & 4 repeat auto OEMs in 2025 Inorganic growth  Jan. 2026 – Cycuity  Dec. 2022 – Semifore  Nov. 2020 – Magillem Financial Performance  Free cash flow positive – 2025  Strong Balance sheet, no debt  Customer, geography, application balance for sustainable growth  While funding a robust R&D program

Page 14

Arteris Acquires Cycuity © 2026 Arteris, Inc.14  Advantage: Cycuity’s technology and expertise strengthens Arteris’ product portfolio, enabling chip designers to understand and improve data movement cybersecurity across IP blocks, chiplets and SoCs.  Challenge: Silicon vulnerabilities can result in compromised systems exposing unprotected information, a trend accelerated by the proliferation of AI and chiplets.  Opportunity: Semiconductor cybersecurity hardware becoming critical to all types of chip designs. All semiconductor companies can use the Cycuity security rule assurance software.

Page 15

Cycuity – Proactive Security Assurance at Every Step of Chip Design © 2026 Arteris, Inc.15 Semiconductor Cybersecurity Assurance Software  Scalable security protection verification – From block level to full SoC, including firmware/software  Integrated into existing RTL verification flows – Based on simulation and emulation  Documented security for certification & compliance  Example applications: ASICs, Processors, SoCs, FPGAs, IP Components Solution at a Glance  Based on information flow technology  Provides coverage metrics to drive security signoff  Support for ISO/SAE 21434 vehicle cybersecurity Aerospace & Defense Automotive Enterprise Computing Consumer Electronics

Page 16

© 2026 Arteris, Inc. 16 Arteris Revenue Growth Strategy  Anticipated organic AIP license revenue of high teens/low 20s% CAGR driven by:  AI from data center to smart edge  Growth in Multi-Die / Chiplet designs  Microcontroller (MCU) support  FlexGen Smart NoC IP deployments  IP and SW new product releases  Royalty revenue est. of 30%+ CAGR  M&A targeted every 1-3 years:  Focus on revenue / cash accretive, profitable opportunities  Synergies with existing product lines and SoC markets AIP License Revenue AIP Royalties M&A Revenue 2025 AI Chiplets New Generation of Products Autonomous Systems Management estimates, 2025 - 2029 Royalties

Page 17

Page 18

4Q/FY 2025 Actuals vs Guidance © 2026 Arteris, Inc.18 In $ millions 4Q 2025 Guidance 4Q 2025 Results FY 2025 Guidance FY 2025 Results Revenue 18.4 – 18.8 20.1 68.8 – 69.2 70.6 Above top-end of guidance ranges ACV + Royalties 74 – 78 83.6 74 – 78 83.6 Above top-end of guidance ranges Non-GAAP Operating Income (Loss)* (3.3) – (2.3) (2.2) (13.5) – (12.5) (12.5) At top-end of guidance ranges Free Cash Flow* 0.2 – 3.2 3.0 2.5 – 5.5 5.3 At top-end of guidance ranges *Non-GAAP measure: See appendix for reconciliation to closest GAAP measure

Page 19

4Q 2025 Business Highlights 4Q’24 3Q’25 4Q’25 Y/Y FY’24 FY’25 Y/Y Revenue 15.5 17.4 20.1 ▲30% 57.7 70.6 ▲22% ACV + Royalties 65.1 74.9 83.6 ▲28% 65.1 83.6 ▲28% NG OpEx* 16.9 19.5 20.8 ▲23% 67.6 77.2 ▲14% NGOI* (2.8) (3.5) (2.2) ▲21% (14.8) (12.5) ▲16% FCF* (2.7) 2.5 3.0 ▲$5.7M (1.0) 5.3 ▲$6.3M RPO 88.4 105 117 ▲32% 88.4 117 ▲32%  Ended the year with record high Revenue, ACV+R, and RPO  Full year Revenue and ACV + Royalties exceeded the top end of their guidance ranges, increasing 22% and 28% Y/Y , respectively  Non-GAAP operating expense was $77.2M for 2025, up 14% on the full year due to weakening USD increasing the cost of overseas operations, and increased investments in R&D and field application engineering teams  Free cash flow positive in the quarter at $3M and for the year at $5.3M—over $6M Y/Y improvement © 2026 Arteris, Inc.19 *Non-GAAP measure: See appendix for reconciliation to closest GAAP measure

Page 20

© 2026 Arteris, Inc.20 Future Royalty Engine 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 # Designs Royalty Pipeline* "Pre-MP" Four + Years Royalties Third Year Royalties Second Year Royalties First Year Royalties 8% 7% 6% 20%59% Royalty Design Maturity* *Full-year data as of December 31, 2024 Yields majority of royalty $ ~60% of design wins waiting to deliver royalty revenue; >50% of customer designs in production still ramping up

Page 21

Design Wins Result in Future Royalty Expansion © 2026 Arteris, Inc.21 Other Auto Royalty $ • Primarily driven by automotive, but with growing contributions by consumer and enterprise • Increasingly diverse royalty customer base, with 4- 5 customers reporting $100k+ quarterly reports, vs 2020 with 1-2 significant customers, dominated by HiSilicon 2021 2025 $0.0 $1.0 $2.0 $3.0 $4.0 $5.0 $6.0 $7.0 2023Q4 2024Q1 2024Q2 2024Q3 2024Q4 2025Q1 2025Q2 2025Q3 2025Q4 Royalties ($ millions) TTM Variable Royalties Automotive Aerospace & Defense Consumer Communications Enterprise Computing Industrial $0.0 $0.5 $1.0 $1.5 $2.0 $2.5 Variable Royalty Growth and Diversification* Sub-$100k Royalty Customers Customer 1 Customer 2 Customer 3 Customer 4 Customer 5 Customer 6 Customer 7 Customer 8 Customer 9 *Excludes royalty audit recoveries

Page 22

Revenue Derived from 2 Main Sources © 2026 Arteris, Inc.22 License & Support  Fully ratable (since 2Q’23)  2 – 3 year average design term  Long-term CAGR1:high teens – low 20s% Royalties  Long-term CAGR1: ~2x license growth rate  Diverse royalty stream across multiple verticals, dozens of customers Free Cash Flow FCF Leads NGOI  Majority of deals paid up front  Revenue deferred  OpEx as incurred Remaining Performance Obligations (RPO) Essentially deferred revenue on BS Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Cumulative Revenue RPO RPO +32% Y/Y Operating Expense  Ongoing scale up R&D / Channel investment  Operating leverage from G&A Key Financial Parameters 1Management estimates, 2025 - 2029 Illustrative example based on historic performance and not necessarily indicative of future results 87% 13%

Page 23

FY 2026 Guidance Guidance © 2026 Arteris, Inc.23 1Q 2026 Guidance ACV + Royalties1 $85M - $89M Revenue2 $20.5M - $21.5M Non-GAAP Op. Income ($3.5M) – ($2.5M) Free Cash Flow ($1.5M) – $1.5M ACV + Royalties3 $100M - $104M Revenue4 $89M - $93M Non-GAAP Op. Income ($9M) – ($5M) Free Cash Flow $5M – $9M 1. 87M at the midpoint, +$20.2M Y/Y (+30%) 2.21M at the midpoint, +$4.5M Y/Y (+27%) 3. 102M at the midpoint, +$18.4M Y/Y (+22%) 4. 91M at the midpoint, +$20.4M Y/Y (+29%) Arteris has not provided a quantitative reconciliation of its 4Q 2025 or FY 2025 guidance for non- GAAP operating income or free cash flow, in either case, to the closest GAAP measure, within this press release because the Company is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. These items include, but are not limited to, inventory valuation adjustment and equity securities fair value adjustment. These items, which could materially affect the computation of forward-looking GAAP measures, are inherently uncertain and depend on various factors, some of which are outside of the Company’s control.

Page 24

Arteris, Inc. All rights reserved worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other Arteris marks found at https://www.arteris.com/trademarks are trademarks or registered trademarks of Arteris, Inc. or its subsidiaries. All other trademarks are the property of their respective owners. Thank you 24 © 2026 Arteris, Inc.

Page 25

Appendix - Non-GAAP Financial Measures © 2026 Arteris, Inc.25 To supplement our financial results, which are prepared and presented in accordance with GAAP, we use certain non-GAAP financial measures, as described below, to understand and evaluate our core performance. These non-GAAP measures, which may be different than similarly-titled measures used by other companies, are presented to enhance investors’ overall understanding of our financial performance and should not be considered in isolation, as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. We define "Non-GAAP gross profit" as GAAP gross profit, adjusted for stock-based compensation expense and amortization of acquired intangible assets included in cost of revenue. We define “Non-GAAP operating expenses” as GAAP operating expenses, adjusted for stock-based compensation and amortization of acquired intangible assets. We define “Non-GAAP operating income (loss)” as GAAP operating income (loss) adjusted to exclude stock-based compensation and amortization of acquired intangible assets. The above items are excluded from our Non-GAAP gross profit, Non-GAAP operating expenses and Non-GAAP operating income (loss) because these items are non-cash in nature, or are not indicative of our core operating performance, and render comparisons with prior periods and competitors less meaningful. We believe Non-GAAP gross profit, Non-GAAP operating expenses and Non-GAAP operating income (loss) provide useful supplemental information to investors and others in understanding and evaluating our results of operations, as well as provide a useful measure for period-to-period comparisons of our business performance. We define free cash flow as net cash provided by (used in) operating activities less cash used for purchases of property and equipment. We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors, even if negative, about the amount of cash used in our operations other than that used for investments in property and equipment.

Page 26

Appendix - GAAP To Non-GAAP Reconciliation Operating expenses © 2026 Arteris, Inc.26 Three Months Ending: Twelve Months Ending: In $ thousands Dec 31, Sep 30, Dec 31, Dec 31, Dec 31, 2024 2025 2025 2024 2025 Operating expenses 21,016 24,356 26,743 83,358 96,821 Less: Stock-based compensation expense 3,944 4,728 4,399 15,155 17,499 Amortization of acquired intangible assets 167 167 140 618 641 Acquisition-related costs - - 1,448 - 1,448 Non-GAAP operating expenses 16,905 19,461 20,756 67,585 77,233

Page 27

Appendix - GAAP To Non-GAAP Reconciliation Operating income (loss) © 2026 Arteris, Inc.27 Three Months Ending: Twelve Months Ending: In $ thousands Dec 31, Sep 30, Dec 31, Dec 31, Dec 31, 2024 2025 2025 2024 2025 Operating Income (Loss) (7,102) (8,714) (8,467) (31,596) (33,137) Add: Stock-based compensation expense 4,131 4,956 4,611 15,938 18,376 Amortization of acquired intangible assets 216 217 190 817 841 Acquisition-related costs - - 1,448 - 1,448 Non-GAAP Operating Income (Loss) (2,755) (3,541) (2,218) (14,841) (12,472)

Page 28

Appendix –Free Cash Flow © 2026 Arteris, Inc.28 Three Months Ending: Twelve Months Ending: In $ thousands Dec 31, Sep 30, Dec 31, Dec 31, Dec 31, 2024 2025 2025 2024 2025 Net cash (used in) provided by operating activities (2,631) 3,187 3,170 (720) 6,733 Less: Purchase of property and equipment (50) (716) (134) (324) (1,388) Free cash flow (2,681) 2,471 3,036 (1,044) 5,345

Page 29

License Fee/Royalty License/support Appendix - Arteris Business Model Arteris customers have delivered over 4 Billion chips/chiplets based on over 925 SoC projects © 2026 Arteris, Inc.29 Customer Evaluation & Acquisition Customer Product SoC Design Cycle Customer System Design In Cycle OEM Customer SoC Production 6-9 months 12-36 months 7-24 months 3-10 years, depending on segment Ratable License Fee / S&M Royalty Royalty Royalty Royalty Royalty Year 0 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 … Year N-1 Year N Ratable License Fee / S&M Ratable License Fee/ S&M Semiconductor or System Co. OEM Semi sells SoCs to OEM OEM Delivers Electronic Systems Arteris Revenue & Cash In Streams

Page 30

Appendix - License Revenue / ACV / RPO Model Example $3M deal, 36-month license term © 2026 Arteris, Inc.30 $3M / 3 Yr Deal Signed 12/29/24 $3M RPO amortizes into GAAP revenue over 3 years RPO ACV 1Q 25 2Q 25 3Q 25 4Q 25 1Q 26 2Q 26 3Q 26 4Q 26 1Q 27 2Q 27 3Q 27 4Q 27 Revenue FY 25 $1M FY 26 $1M FY 27 $1M 4Q ’24 $1M 1Q ’25 $1M 2Q ’25 $1M 3Q ’25 $1M 4Q ‘25 $1M FY 25 $1M FY 26 $1M 1Q ’26 $1M 2Q ’26 $1M 3Q ’26 $1M 4Q ’26 $1M 1Q ’27 $1M 2Q ’27 $1M 3Q ’27 $1M 4Q24 ACV FY25 revenue

Slides